p63、34βE12和S-100在前列腺穿刺活检组织中的表达及其对前列腺癌的诊断价值  

Significance of tissue-immune-related indicators in biopsy of prostate and its diagnostic value in prostate cancer

作　　者：骆杨 班德文 何婷玉 胡伟 LUO Yang;BAN Dewen;HE Tingyu;HU Wei(Department of Oncology,Xinyang Central Hospital,Xinyang,Henan,464000,China;Department of Urology,Xinyang Central Hospital;Department of Pathology,Xinyang Central Hospital;Department of Pharmacy,Xinyang Central Hospital)

机构地区：[1]信阳市中心医院肿瘤科,河南信阳464000 [2]信阳市中心医院泌尿外科 [3]信阳市中心医院病理科 [4]信阳市中心医院药学部

出　　处：《临床泌尿外科杂志》2020年第9期721-724,共4页Journal of Clinical Urology

摘　　要：目的:研究p63、角蛋白-903(34βE12)和S-100等组织免疫相关指标在前列腺穿刺活检组织中的表达及诊断价值。方法:选择2017年1月-2020年1月经我院收集的前列腺穿刺活检标本90例,其中前列腺癌58例,良性前列腺增生32例。采用免疫组织化学法检测p63、34βE12和S-100在不同前列腺病变组织中的表达情况,探讨其对前列腺癌的诊断价值。结果:p63在58例前列腺癌组中无弱阳性、阳性表达,58例(100.00%)阴性表达;在32例良性前列腺增生组中29例(90.63%)阳性表达,3例(9.38%)弱阳性表达,无阴性,阳性率100%(32/32);前列腺癌组患者p63阳性表达率显著低于良性前列腺增生组(P<0.05);34βE12在58例前列腺癌组中有2例(3.45%)弱阳性表达,56例(96.55%)阴性表达,阳性率3.45%(2/58);在32例良性前列腺增生组中29例(90.63%)阳性表达,3例(9.38%)弱阳性表达,无阴性,阳性率100%(32/32);前列腺癌组患者34βE12阳性表达率显著低于良性前列腺增生组(P<0.05);S-100在58例前列腺癌组中有45例(77.59%)阳性表达,2例(3.45%)弱阳性表达,11例(18.97%)阴性表达,阳性率81.03%(47/58);在32例良性前列腺增生组中有4例(12.50%)阳性表达,3例(9.38%)弱阳性表达,25例(78.13%)阴性表达,阳性率21.88%(7/32);前列腺癌组患者S-100阳性表达率显著高于良性前列腺增生组(P<0.05);p63、34βE12和S-100表达水平与非前列腺癌疾病存在相关性(P<0.05)。结论:p63、34βE12和S-100蛋白联合用于检测前列腺癌,可提高其诊断准确率,且对前列腺疾病有鉴别诊断作用。Objective: To investigate the significance of p63, basal cell-specific anti-cytokeratin antibody(34βE12) and S-100 in prostate biopsy. Method: Ninety biopsy specimens of prostate in our hospital from January 2017 to January 2020 were collected, including 58 cases of prostate cancer and 32 cases of benign prostatic hyperplasia. Immunohistochemistry was used to detect the expression of p63, 34βE12 and S-100 in prostate lesions, and their value in the diagnosis of prostate cancer was analyzed. Result: P63 in prostate cancer group were all negative(58/58, 100.00%), and no weak positive or positive expression was found. Among 32 cases in non-prostate cancer group, p63 was positive in 29 cases(90.63%) and weak positive in 3 cases(9.38%), with a positive rate of 100%(32/32). Among 58 cases in prostate cancer group, 34βE12 was weak positive in 2 cases(3.45%) and negative in 56 cases(96.55%), with a positive rate of 3.45%(2/58). Among 32 cases in non-prostate cancer group, 34βE12 was positive in 29 cases(90.63%) and weak positive in 3 cases(9.38%), with a positive rate of 100%(32/32). The 34βE12 positive expression rate in prostate cancer group was significantly lower than that in benign prostate hyperplasia group(P<0.05). Among 58 cases in prostate cancer group, S-100 was positive in 45 cases(77.59%), weak positive in 2 cases(3.45%) and negative in 11 cases(18.97%), with a positive rate of 81.03%(47/58). Among 32 cases in non-prostate cancer group, S-100 was positive in 4 cases(12.50%), weak positive in 3 cases(9.38%) and negative in 25 cases(78.13%), with a positive rate of 21.88%(7/32). The S-100 positive expression rate in prostate cancer group was significantly higher than that in benign prostate hyperplasia group(P<0.05). P63, 34βE12 and S-100 were significantly correlated with non-prostate cancer diseases(P<0.05). Conclusion: Combined detection of p63, 34βE12 and S-100 can improve the diagnosis accuracy of prostate cancer.

关 键 词：前列腺癌 穿刺活检 P63 34ΒE12 S-100 

分 类 号：R737.25[医药卫生—肿瘤]